
    
      Phase 2a, randomized, placebo-controlled, pilot study in up to 21 adult patients with
      moderate to severe CCh. Eligible patients will be randomly assigned in a 2:1 (active:placebo)
      ratio to one of two treatment groups, LO2A or placebo.

      This study with 4 visits, will consist of a screening period of up to 2 weeks and a 3-month
      treatment period (topical, OU, QID application of eye drops).
    
  